Business
Hoth Therapeutics Expands HT-001 Development with Patent Filings Targeting Drug-Induced Hypersensitivity, Radiotherapy-Induced Rash, and MENIN Inhibitor-Associated Skin Toxicities
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company developing next-generation treatments for dermatological and inflammatory conditions, today announced the expansion of its intellectual property portfolio for HT-001, its lead topical therapeutic candidate. The Company has filed multiple U.S. Provisional Patent Applications covering novel dermatological indications, broadening the commercial and clinical potential of HT-001.
About this update from Hoth Therapeutics, Inc.
[{"type":"text","content":"MENIN inhibitors are a promising class of targeted oncology drugs in development for acute leukemias and certain solid tumors, but their use is often limited by severe dermatological side effects. HT-001 aims to address these toxicities, helping patients remain on therapy and realize the full benefit of treatment.","length":315,"tagName":"p"},{"type":"text","content":"Key Highlights","length":14,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"U.S. Provisional Patents filed expanding HT-001's therapeutic reach.","length":72,"tagName":"p"}]},{"val":[{"type":"text","content":"Indications covered:","length":20,"tagName":"p"}]},{"val":[{"type":"text","content":"MENIN inhibitors are an emerging oncology class with significant promise in acute leukemias and select solid tumors, but treatment-limiting rashes remain a major clinical challenge.","length":181,"tagName":"p"}]},{"val":[{"type":"text","content":"HT-001 designed to improve tolerability of cancer therapies by addressing dermatological side effects, potentially enabling patients to remain on therapy longer.","length":161,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":434,"olType":false},{"type":"text","content":"NEW YORK, Sept. 24, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company developing next-generation treatments for dermatological and inflammatory conditions, today announced the expansion of its intellectual property portfolio for HT-001, its lead topical therapeutic candidate. The Company has filed multiple U.S. Provisional Patent Applications covering novel dermatological indications, broadening the commercial and clinical potential of HT-001.","length":506,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Hoth Therapeutics Inc.)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Hoth Therapeutics Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":68,"url":"https://media.zenfs.com/en/prnewswire.com/a168928171a9653a66d38f6c5e666beb"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/r2Ptel_Ut1tf_dA2SUFY0g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTEyMDtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/a168928171a9653a66d38f6c5e666beb","width":400,"height":68}},"href":"https://mma.prnewswire.com/media/644804/Hoth_Therapeutics_Log...